SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 6, 2004
IntraBiotics Pharmaceuticals, Inc.
| Delaware | 0-29993 | 94-3200380 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
||
2483 East Bayshore Road, Suite 100
Palo Alto, California 94303
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 526-6800
Not Applicable
| Item 8.01 Other Events. | ||||||||
| Item 9.01 Financial Statements and Exhibits. | ||||||||
| SIGNATURE | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 8.01 Other Events.
On October 6, 2004, IntraBiotics Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it had retained Lazard to advise the Company in evaluating strategic options.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press release dated October 6, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INTRABIOTICS PHARMACEUTICALS, INC. | ||||
| Date: October 7, 2004 | /s/ David Tucker David Tucker Principal Financial Officer |
EXHIBIT INDEX
| Exhibit | ||||||
| Number | Description | |||||
| 99.1 | Press release dated October 6, 2004. | |||||